Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – but could struggle to displace rival drugs from Bristol-Myers Squibb and Merck & Co.

Roche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple negative breast cancer, and untreated lung cancer, as the company plays catch-up with Merck ...

Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following ...

Half of the patients in a small trial for an experimental pancreatic cancer vaccine by Roche and BioNTech showed survival ...

and Tecentriq around the decade's end. The analyst further identified a significant near-term risk to Roche's earnings estimates. This risk is associated with the upcoming data from the DB11 trial ...

New Zealanders now have funded access to a global standard of care treatment for a form of liver cancer, Hepatocellular Carcinoma (HCC), which, unlike many other cancers has a rapidly increasing rate ...

Pelareorep combined with modified FOLFIRINOX, with or without Tecentriq, shows an acceptable safety profile in metastatic PDAC patients. All patients experienced side effects, with some severe cases, ...

Roche’s shares have risen 10.6% year to date ... CHF 3.9 billion on strong demand in all regions. Immuno-oncology drug Tecentriq’s (for advanced lung cancer, urothelial cancer and breast ...

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2 ; DLBCL-an ...

Study participants first received surgery, followed by the vaccine and Roche's immunotherapy Tecentriq (atezolizumab), and finally chemotherapy. At a median follow-up of 3.2 years, six of the ...